Jason D Jones1, Monica E Calkins2, J Cobb Scott3, Emily C Bach2, Raquel E Gur4. 1. Neuropsychiatry Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: jasjones@upenn.edu. 2. Neuropsychiatry Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 3. Neuropsychiatry Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; VISN 4 Mental Illness Research, Education, and Clinical Center, Philadelphia VA Medical Center, Philadelphia, Pennsylvania. 4. Neuropsychiatry Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: raquel@upenn.edu.
Abstract
PURPOSE: To examine how cannabis use and polysubstance use among cannabis users relate to psychosis spectrum (PS) symptoms in a large community-based sample of U.S. youth. METHODS: Four thousand one hundred seventy-one youths (aged 14-21 years; mean = 16.90 years, SD = 1.85; 55% female) from the Philadelphia Neurodevelopmental Cohort completed assessments of substance use, PS symptoms, and confounding variables (e.g., demographics, comorbid psychopathology, and trauma exposure). RESULTS: After adjusting for confounds, cannabis use by itself was not associated with increased odds of being classified as "psychosis spectrum." However, cannabis use in combination with tobacco or other substance use was associated with increased odds of PS classification (adjusted odds ratios [ORs] = 1.37-1.76). Follow-up symptom-level analyses revealed that cannabis use in combination with other substances was associated with subclinical positive symptoms (ORs = 1.95 and 2.24) and frequent cannabis use was associated with subclinical negative/disorganized symptoms (OR = 2.14). However, these symptom-level findings were reduced to trends after correction for multiple comparisons. Neither cannabis use nor polysubstance use was associated with threshold delusions or hallucinations. CONCLUSIONS: After adjusting for important confounds, there was minimal evidence for associations between cannabis use by itself and PS symptoms. More compelling evidence emerged for associations between polysubstance use among cannabis users and PS symptoms. This study highlights the importance of considering polysubstance use and confounds when examining associations between cannabis use and PS symptoms. Further longitudinal research is necessary to determine whether these findings represent causal associations or shared genetic and/or environmental vulnerability for substance use and PS symptoms.
PURPOSE: To examine how cannabis use and polysubstance use among cannabis users relate to psychosis spectrum (PS) symptoms in a large community-based sample of U.S. youth. METHODS: Four thousand one hundred seventy-one youths (aged 14-21 years; mean = 16.90 years, SD = 1.85; 55% female) from the Philadelphia Neurodevelopmental Cohort completed assessments of substance use, PS symptoms, and confounding variables (e.g., demographics, comorbid psychopathology, and trauma exposure). RESULTS: After adjusting for confounds, cannabis use by itself was not associated with increased odds of being classified as "psychosis spectrum." However, cannabis use in combination with tobacco or other substance use was associated with increased odds of PS classification (adjusted odds ratios [ORs] = 1.37-1.76). Follow-up symptom-level analyses revealed that cannabis use in combination with other substances was associated with subclinical positive symptoms (ORs = 1.95 and 2.24) and frequent cannabis use was associated with subclinical negative/disorganized symptoms (OR = 2.14). However, these symptom-level findings were reduced to trends after correction for multiple comparisons. Neither cannabis use nor polysubstance use was associated with threshold delusions or hallucinations. CONCLUSIONS: After adjusting for important confounds, there was minimal evidence for associations between cannabis use by itself and PS symptoms. More compelling evidence emerged for associations between polysubstance use among cannabis users and PS symptoms. This study highlights the importance of considering polysubstance use and confounds when examining associations between cannabis use and PS symptoms. Further longitudinal research is necessary to determine whether these findings represent causal associations or shared genetic and/or environmental vulnerability for substance use and PS symptoms.
Authors: Theodore D Satterthwaite; Daniel H Wolf; Monica E Calkins; Simon N Vandekar; Guray Erus; Kosha Ruparel; David R Roalf; Kristin A Linn; Mark A Elliott; Tyler M Moore; Hakon Hakonarson; Russell T Shinohara; Christos Davatzikos; Ruben C Gur; Raquel E Gur Journal: JAMA Psychiatry Date: 2016-05-01 Impact factor: 21.596
Authors: Monica E Calkins; Tyler M Moore; Kathleen R Merikangas; Marcy Burstein; Theodore D Satterthwaite; Warren B Bilker; Kosha Ruparel; Rosetta Chiavacci; Daniel H Wolf; Frank Mentch; Haijun Qiu; John J Connolly; Patrick A Sleiman; Hakon Hakonarson; Ruben C Gur; Raquel E Gur Journal: World Psychiatry Date: 2014-10 Impact factor: 49.548
Authors: Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis Journal: Lancet Date: 2007-07-28 Impact factor: 79.321
Authors: Sheila Shanmugan; Daniel H Wolf; Monica E Calkins; Tyler M Moore; Kosha Ruparel; Ryan D Hopson; Simon N Vandekar; David R Roalf; Mark A Elliott; Chad Jackson; Efstathios D Gennatas; Ellen Leibenluft; Daniel S Pine; Russell T Shinohara; Hakon Hakonarson; Ruben C Gur; Raquel E Gur; Theodore D Satterthwaite Journal: Am J Psychiatry Date: 2016-01-22 Impact factor: 18.112
Authors: Jason D Jones; Rhonda C Boyd; Monica E Calkins; Annisa Ahmed; Tyler M Moore; Ran Barzilay; Tami D Benton; Raquel E Gur Journal: Pediatrics Date: 2019-01-14 Impact factor: 7.124
Authors: J Cobb Scott; Samantha T Slomiak; Jason D Jones; Adon F G Rosen; Tyler M Moore; Ruben C Gur Journal: JAMA Psychiatry Date: 2018-06-01 Impact factor: 21.596